Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.

Effect of GLP-1 receptor agonists on heart failure events in patients with obesity without diabetes In the SELECT RCT, the risk of HF events was numerically reduced, but did not reach statistical significance (RR 0.79, 95% CI 0.61–1.04) ( Figure 1 ), with the trial powered for a primary outcome of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). 13 Subgroup analysis Effect of GLP-1 receptor agonists in patients without baseline heart failure In patients without baseline HF, HF events were reduced by 19% by GLP-1 receptor agonist therapy compared with placebo (RR 0.81, 95% CI 0.72–0.90; ARR 0.60%, 95% CI 0.32%-0.89%; NNT 167, 95% CI 113–313) ( Figure 2 ).

also in 111,027 other papers